Loading...
•
Mar 31, 2022
Harmony Biosciences Q1 2022 Earnings Report
Reported financial results and business updates for the quarter ended March 31, 2022.
Key Takeaways
Harmony Biosciences reported a strong first quarter in 2022, with WAKIX net revenue reaching $85.3 million, a 43% increase compared to the same period in 2021, and GAAP net income of $21.5 million, or $0.35 per diluted share.
WAKIX net revenue reached $85.3 million, a 43% increase compared to Q1 2021.
WAKIX surpassed $500 million in cumulative net revenue since launch.
Phase 3 clinical trial was initiated in patients with Idiopathic Hypersomnia.
GAAP net income was $21.5 million, or $0.35 per diluted share.
Revenue by Segment
Forward Guidance
Harmony Biosciences is focused on acquiring new assets and evolving into a leading rare neurology company with a broad portfolio of innovative products. Topline data from the Phase 2 proof-of-concept trial in PWS is anticipated in the second half of 2022, and DM1 topline data is expected in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...